<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368839">
  <stage>Registered</stage>
  <submitdate>27/06/2015</submitdate>
  <approvaldate>9/07/2015</approvaldate>
  <actrnumber>ACTRN12615000708550</actrnumber>
  <trial_identification>
    <studytitle>Analgesic efficacy of paravertebral dexmedetomidine in children undergoing renal surgery</studytitle>
    <scientifictitle>In children undergoing renal surgery, does paravertebral dexmedetomidine added to bupivacaine, compared to paravertebral bupivacaine only, reduce postoperative opioid consumption?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>postoperative analgesia for pediatric patients undergoing renal surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>After  induction of anesthesia and before skin incision, for group PD, with the patient in the lateral decubitus position and the operated side facing upwards. Needle insertion will be  made at an easily palpated single low thoracic level (Th1012) lateral to the spinal process. The distance from the midline will be (approximating the distance between the patients two adjacent spinous processes). A 22 G Tuohy needle will be inserted perpendicularly to the skin in all planes until contact with the transverse process. The needle will be then advanced under or over the transverse process and after piercing the costo-transverse ligament, the paravertebral space was identified by loss of resistance to air. After careful aspiration, a single bolus dose of 0.5 ml / kg  of Bupivacaine 0.25% and 1.5 mic /kg dexmedetomidine will be injected.</interventions>
    <comparator>for group PB, a single bolus dose of 0.5 ml / kg  of Bupivacaine 0.25% only will be injected in the paravertebral space in the low thoracic level (Th1012)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>postoperative opioid consumption of patients recorded by research nurse.
</outcome>
      <timepoint>postoperative 24 h</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first analgesic request recorded by research nurse</outcome>
      <timepoint>postoperative 24 h </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain intensity measured by visual analogue scale and FLACC score recorded by research nurse</outcome>
      <timepoint>postoperative, 0 h (immediately postoperative), 1h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1-Renal surgery
2-patients with physical status American Society of Anaesthesiologist (ASA) I , II and III</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1-contraindication to PVB (infection at site of injection, coagulopathy, vertebral anomalies)
2- allergy to drugs used in the study
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/09/2015</anticipatedstartdate>
    <actualstartdate>1/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>diab fuad hetta</primarysponsorname>
    <primarysponsoraddress>organization address: south egypt cancer institute, 2 el methaque st., assuit university, assuit city, 71111, egypt</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>none</fundingname>
      <fundingaddress>none</fundingaddress>
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>noha esmail ibrahim</sponsorname>
      <sponsoraddress>organization address: faculty of medicine, 1 university st., assuit university,
assuit city,71111, egypt</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Evaluation of postoperative analgesic efficacy of paravertebral dexmedetomidine when added to bupivacaine in pediatric patients undergoing renal surgery</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>faculty of medicine, assuit university ethical committee</ethicname>
      <ethicaddress>organization address: faculty of medicine, 1 university st., assuit university, assuit city,71111, egypt</ethicaddress>
      <ethicapprovaldate>28/08/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>15/08/2015</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>organization address: south egypt cancer institute, 2 el methaque st., assuit university, assuit city, 71111, egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta25@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>organization address: south egypt cancer institute, 2 el methaque st., assuit university, assuit city, 71111, egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta25@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>organization address: south egypt cancer institute, 2 el methaque st., assuit university, assuit city, 71111, egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta25@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>